NO993979L - FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor - Google Patents

FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor

Info

Publication number
NO993979L
NO993979L NO993979A NO993979A NO993979L NO 993979 L NO993979 L NO 993979L NO 993979 A NO993979 A NO 993979A NO 993979 A NO993979 A NO 993979A NO 993979 L NO993979 L NO 993979L
Authority
NO
Norway
Prior art keywords
alzheimer
onset
disease
composition
procedures
Prior art date
Application number
NO993979A
Other languages
English (en)
Norwegian (no)
Other versions
NO993979D0 (no
Inventor
Egon Novak
Original Assignee
Forbes Medi Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi Tech Inc filed Critical Forbes Medi Tech Inc
Publication of NO993979D0 publication Critical patent/NO993979D0/no
Publication of NO993979L publication Critical patent/NO993979L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO993979A 1997-12-18 1999-08-18 FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor NO993979L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/993,901 US5985936A (en) 1997-12-18 1997-12-18 Method of preventing and delaying onset of Alzheimer's disease and composition therefor
PCT/CA1998/001147 WO1999032097A2 (fr) 1997-12-18 1998-12-18 Procede pour prevenir et retarder l'apparition de la maladie d'alzheimer, et composition utilisee a cet effet

Publications (2)

Publication Number Publication Date
NO993979D0 NO993979D0 (no) 1999-08-18
NO993979L true NO993979L (no) 1999-10-13

Family

ID=25540052

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993979A NO993979L (no) 1997-12-18 1999-08-18 FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor

Country Status (18)

Country Link
US (1) US5985936A (fr)
EP (1) EP0967982A2 (fr)
CN (1) CN1252724A (fr)
AU (1) AU1656099A (fr)
BG (1) BG103740A (fr)
BR (1) BR9807577A (fr)
CA (1) CA2281710A1 (fr)
EE (1) EE9900354A (fr)
GE (1) GEP20022783B (fr)
HU (1) HUP0100737A3 (fr)
LT (1) LT4801B (fr)
LV (1) LV12438B (fr)
MD (1) MD1920F2 (fr)
NO (1) NO993979L (fr)
PL (1) PL335421A1 (fr)
RU (1) RU2173151C2 (fr)
SK (1) SK112999A3 (fr)
WO (1) WO1999032097A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
JP2003523948A (ja) * 1999-11-04 2003-08-12 アンドルクス コーポレーション アミロイドβ前駆体障害の治療法
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
EP1274319B1 (fr) 2000-04-14 2009-08-12 Mars, Incorporated Compositions et methodes permettant d'ameliorer la sante vasculaire
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
DK1355644T3 (da) 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
DE60224078T2 (de) * 2001-02-12 2008-12-04 N.V. Organon Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind.
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
WO2004043457A1 (fr) 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
NZ567324A (en) * 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
JP2006519869A (ja) * 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
CA2517571C (fr) 2003-03-07 2011-07-05 Schering Corporation Azetidinones substituees , procedes pour leur preparation, formulations et utilisations de celles-ci
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20080182801A1 (en) * 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
US20050277129A1 (en) * 2004-01-22 2005-12-15 Genaissance Pharmaceuticals APOE genetic markers associated with age of onset of Alzheimer's disease
AU2005319578A1 (en) * 2004-11-24 2006-06-29 Neopro Labs, Llc Methods and compositions for treating conditions
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
RU2297860C1 (ru) * 2006-02-07 2007-04-27 Иван Васильевич Максимович Способ эндоваскулярного лечения болезни альцгеймера
MX2010009649A (es) * 2008-03-27 2010-12-17 Evotecv Neurosciences Gmbh Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda.
WO2010104375A1 (fr) * 2009-03-12 2010-09-16 N.V. Nutricia Stigmastérol pour le traitement de la maladie d'alzheimer
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10307450B2 (en) 2010-01-11 2019-06-04 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
US9376481B2 (en) 2011-04-26 2016-06-28 The Regents Of The University Of California Methods of promoting CNS neuronal repair by inhibiting LRP-1
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
WO2015123618A1 (fr) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Procédé d'augmentation de l'expression du gène bcl2
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
US11331291B2 (en) 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
MX2020002884A (es) 2017-09-14 2020-10-05 Phoenix Biotechnology Inc Método y composición neuroprotectora mejorada para tratar afecciones neurológicas.
EP3842039A1 (fr) * 2019-12-24 2021-06-30 Folium Biosciences Europe B.V. Complément alimentaire comprenant des cannbinoïdes et des phytostérols pour la maladie d'alzheimer
WO2021130002A1 (fr) 2019-12-24 2021-07-01 Folium Biosciences Europe B.V. Complément alimentaire pour la maladie d'alzheimer
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
CU24748B1 (es) 2022-11-04 2025-04-04 Centro Nac De Biopreparados Nutracéutico para la prevención y tratamiento del deterioro cognitivo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2057531C1 (ru) * 1986-07-01 1996-04-10 Всероссийский научный центр по безопасности биологически активных веществ Средство для стимуляции обучения и памяти
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
SK279476B6 (sk) * 1989-05-17 1998-11-04 Pfizer Deriváty 2-piperidino a 2-pyrolidino-1-alkanolov a
CZ284157B6 (cs) * 1992-12-17 1998-08-12 Pfizer Inc. Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi
WO1994018994A1 (fr) * 1993-02-23 1994-09-01 Pharmakon Usa, Inc. Composition therapeutique a base d'herbes
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
ES2464465T3 (es) * 1994-09-29 2014-06-02 Pharmachem Laboratories, Inc. Composiciones de esteroles a partir de jabón de pulpa
CN1179903A (zh) * 1996-10-09 1998-04-29 李辉 营养丝米粉
WO1998051302A1 (fr) * 1997-05-15 1998-11-19 University Of Washington Composition et procedes de traitement de la maladie d'alzheimer et autres amyloidoses

Also Published As

Publication number Publication date
MD990262A (en) 2000-06-30
WO1999032097A2 (fr) 1999-07-01
PL335421A1 (en) 2000-04-25
EP0967982A2 (fr) 2000-01-05
BG103740A (en) 2000-05-31
HUP0100737A3 (en) 2002-07-29
HUP0100737A2 (hu) 2001-09-28
EE9900354A (et) 2000-02-15
LV12438B (en) 2000-09-20
BR9807577A (pt) 2001-08-07
CA2281710A1 (fr) 1999-07-01
AU1656099A (en) 1999-07-12
CN1252724A (zh) 2000-05-10
WO1999032097A3 (fr) 1999-09-02
GEP20022783B (en) 2002-09-25
US5985936A (en) 1999-11-16
MD1920F2 (ro) 2002-05-31
SK112999A3 (en) 2001-11-06
LT4801B (lt) 2001-06-25
LT99114A (lt) 2001-01-25
LV12438A (en) 2000-03-20
RU2173151C2 (ru) 2001-09-10
NO993979D0 (no) 1999-08-18

Similar Documents

Publication Publication Date Title
NO993979L (no) FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
ATE324872T1 (de) Orale pharmazeutische zusammensetzung mit verzögerter wirkstofffreigabe von protonenpumpen- hemmern
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
IS4972A (is) Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
ES2192227T3 (es) Composiciones farmaceuticas orales con liberacion retardada de inhibidores reversibles de las bombas de protones.
BR9713866A (pt) Composição farmacéutica
NO2007004I1 (no) Mycofenolsyre = (E)-6-(1,3-dihydro-4-hydroksy-6-metoksy-7-metyl-3-oksajsobenzofuran-5-yl)-4-, metylheks-4-ensyre
NO971206D0 (no) Forlenget-frigjöringsformulering
ATE197897T1 (de) Hautpflegemittel
NO20016007L (no) Rekombinant anti-CD40-antistoff og anvendelser derav
NO951613L (no) Ikke-peptidyl tachykinin reseptorantagonister
ES2158494T3 (es) Caramelos que contienen un edulcorante.
DK0998287T3 (da) Anvendelse af levobupivacain
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
DK1073456T3 (da) Anvendelse af osteoprotegerin til forebyggelse og behandling af kardiovaskulære sygdomme
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
FI972988A0 (fi) Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
NO20005981L (no) Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- <kappa>B
DK0821588T3 (da) Levobupivacain og anvendelse heraf som et anæstetikum til gravide kvinder
WO1999012945A3 (fr) Derives de glycosylamine hydrophobes, compositions a base de ces derives et procedes d'utilisation
DK1227826T3 (da) Sammensætninger omfattende et ekstrakt af Perna canaliculus, methylsulfonylmethan og glucosamid samt anvendelsen heraf

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application